Odonate Inc (ODTC) Giá

Odonate, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improve and extend the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The firm is no longer in development of tesetax.